Different Treatment Modalities in the Management of the Painful Crisis in Pediatric Sickle- Cell Anemia

• Status: Completed
• Trial end date: 2020-12-10
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the present study is comparing the effectiveness of different treatment regimens for investigating the therapeutic potential for each one in management of Vaso-occlusive pain in pediatric sickle cell disease. In addition, investigators apply the Cost-effectiveness analysis (CEA) as a form of economic analysis that compares the relative costs and outcomes (effects) for different treatment regimens on vaso-occlusive painful crisis.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beni-Suef University
• Collaborators: Benisuef university hospital; College of Pharmacy,Department of Pharmacy Practice,University of Arizona; Department of clinical pharmacy, faculty of pharmacy, Beni-suef univeristy; Maternity and Children Hospital, Makkah; University of Arizona
• Treatments: Analgesics; Folic Acid; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxyurea; Morphine; Simvastatin; Vitamin B Complex; Vitamin D; Zinc; Zinc Sulfate

Criteria

Inclusion Criteria:

Any case with the full manifestation of sickle cell disease accompanied by acute painful crisis aged from 5-15 years old.

Exclusion Criteria:

1. The presence of any other chronic illness.

2. Patient age>18 years old or < 3 years old.

3. Patients with hepatic diseases including cholestasis hepatic encephalopathy and jaundice.

4. Patients with renal impairment

5. Diabetic patients